HArmonyCa Lido (2x1,25ml)

This treatment is strictly contraindicated. There is no clinical safety data for hybrid CaHA injectables during pregnancy. We adhere to safety standards and defer treatment until after childbirth.

Patients should avoid alcohol for 24h before and 48h after the procedure. Alcohol is a vasodilator that can exacerbate post-filler swelling and increase the risk of hematomas in the lifting zones.

Injection is not recommended for nursing mothers. It is advised to postpone elective aesthetic procedures until the breastfeeding period has completely concluded.

HArmonyCa works in two phases: the cross-linked HA provides an immediate mechanical lift in the superficial subcutaneous layer, while the CaHA microspheres stimulate fibroblasts over the following weeks. Unlike superficial skin boosters, HArmonyCa rebuilds the skin's architecture for a "bio-armoring" effect.

The formulation contains cross-linked Hyaluronic Acid (20 mg/ml), Calcium Hydroxyapatite microspheres (55.7%), and 0.3% Lidocaine hydrochloride.

Dosage is individualized based on the level of skin laxity. The 1.25 ml syringe volume allows for a more comprehensive treatment of the lateral face compared to standard 1 ml syringes. Typically, one pack (2 syringes) is sufficient for a full lateral lift. Clinicians must note that this product is not intended for the lips or the central face.

Common reactions include temporary swelling, redness, and potential purple bruising. Because of the CaHA component, the treated area may feel firm for several weeks. Follow our expert aftercare guide for recovery protocols. Any skin blanching requires immediate evaluation for vascular occlusion.